Mr. Heppell is the co-founder, President and Director of BC Advantage Funds (VCC) Ltd., a venture fund that invests in and builds technology, life science and clean technology companies. His first fund, the Advantage Life Sciences I Fund, won the Canadian Venture Capital Deal of the Year Award in 2006. Earlier in his career, he practiced corporate securities law with Fasken Martineau DuMoulin and later served as President and CEO of Catalyst Corporate Finance Lawyers. Mr. Heppell has also helped to build a number of life science companies, including Aspreva Pharmaceuticals (acquired by Galenica Ltd. SW: GALN), Immgenics (acquired by Amgen NASDAQ: AMGN), Inovio Pharmaceuticals (NASDAQ: INO), and Sophiris Bio Inc. (NASDAQ: SPHS). He earned a BSc in microbiology and a law degree from the University of British Columbia.

Dr. Chris Thorton has 30 years of experience in biotech and pharmaceutical leadership, product development, and clinical and regulatory management. He has completed partnerships and collaborations with pharmaceutical, biotech, and medical device companies and  has raised more than $150 million to advance product development into clinical stage, regulatory approval, and commercialization. He is a former practicing physician and CEO of two public biotech companies: Migenix and GenSci Regeneration Sciences (now part of Integra LifeSciences). Dr. Chris Thorton also currently serves as Director for two biotech companies: OncoSec Medical and Induce Biologics. Prior to his CEO roles, Dr. Chris Thorton was Vice President, Medical and Regulatory Affairs at Biodynamics International (now part of RTI Surgical) and Bentley Pharmaceuticals (now part of Teva Pharmaceuticals). Dr. Chris Thorton received a bachelor’s degree in Chemistry, and MD, and MBA degrees from the University of South Florida and did his medical residency at the University of North Carolina.

Dr. Morello is an accomplished clinician with direct, first-hand experience in the clinical and medical application of cannabinoids. Dr. Morello continues to practice at the Complex Chronic Disease Program at Woman’s Hospital in Vancouver, Canada. He also serves on the Quality Assurance Committee for the College of Naturopathic Physicians of British Columbia and other health and medical panels. He authored Cleanse: The Ultimate Inside Out Approach and The Fiber Miracle, and is a contributing author to A Textbook of Natural Medicine, Alive Magazine, Viva Magazine and other publications. He has made more than 500 medical presentations in the US, Canada, Australia, Germany, and Italy in the last decade. Dr. Morello has a BSc in Cell Biology/Nutrition from the University of British Columbia and a Doctorate in Naturopathic Medicine from Bastyr University.

Mr. Dhillon is the co-founder and director of OncoSec Medical Incorporated, a leading biopharmaceutical company developing cancer immunotherapies for the treatment of solid tumors. Prior to OncoSec, he served as Vice President of Finance and Operations at Inovio Pharmaceuticals, where he raised over $160 million through multiple financings and several licensing transactions. His management experience spans corporate finance, M&A integration, in-licensing of key intellectual property, strategy implementation, corporate transactions and collaborations with leading universities and key global opinion leaders. Mr. Dhillon also the co-founded BeCancerPositive.org, an online community for cancer patients. In 2014, he was a finalist in Ernst & Young’s “Entrepreneur of the Year” competition. Mr. Dhillon holds a BA (Honors) in political science and a minor in business administration from Simon Fraser University.